EGFR Exon20 ion+ mNSCLC

Takeda Presents Positive Results For Mobocertinib in Patients with EGFR Exon20 insertion+ mNSCLC Who Received Prior Platinum-based Chemotherapy

Osaka, Japan & Cambridge, Mass., United States:  Mobocertinib, an oral targeted therapy, demonstrated clinically meaningful responses, with a confirmed objective…

Read More »